Year: 2025

Mowi ASA – Green Bond Mandate Announcement and Fixed Income Investor Meetings

Written by Customer Service on November 25, 2025. Posted in Public Companies.

Bergen, 25 November 2025. Mowi ASA, investment grade rated BBB+ with stable outlook by Nordic Credit Rating, has mandated Danske Bank, DNB Carnegie and Nordea as Global Coordinators and Joint Lead Managers, and ABN AMRO, Crédit Agricole Corporate and Investment Bank, Rabobank and SEB as Joint Lead Managers to arrange a series of physical and virtual fixed income investor meetings commencing today. One or more NOK-denominated senior unsecured green bond issues (swapped to EUR) with a minimum tenor of 5 years may follow, subject to inter alia market conditions. For further information, please contact: Kristian Ellingsen, CFO, +47 905 14 275 Kim Galtung Døsvig, IR Officer & Head of Treasury, +47 908 76 339 About Mowi ASAMowi is one of the world’s leading seafood companies and the largest producer of farm-raised Atlantic salmon...

Sampo plc’s share buybacks 24 November 2025

Written by Customer Service on November 25, 2025. Posted in Public Companies.

Sampo plc, stock exchange release, 25 November 2025 at 8:30 am EET Sampo plc’s share buybacks 24 November 2025 On 24 November 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code) 8,735 10.02 AQEU 96,270 10.04 CEUX 24,999 10.04 TQEX 75,003 10.03 XHELTOTAL 205,007 10.04 * rounded to two decimals On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November...

TCM Group A/S: Interim report Q3 2025

Written by Customer Service on November 25, 2025. Posted in Earnings Releases And Operating Results.

COMPANY ANNOUNCEMENT No. 246/2025 Tvis, 25 November 2025 Interim report Q3 2025 (July 1 – September 30) (All figures in brackets refer to the corresponding period in 2024) Delivering stable sales growth and gross margin improvements despite a volatile market. CEO Torben Paulin:“Sales in the third quarter developed in line with our expectations, with growth recorded in both the B2B and B2C segments. Total sales for the quarter increased by 4% year-on-year to DKK 289 million, corresponding to organic growth of 3%. Order intake improved during the quarter, with high single-digit growth in the core business overall and double-digit growth in the B2C segment. In the B2B segment, project orders declined slightly compared to the prior year, while orders from builders of turnkey residential houses showed a strong positive trend. The...

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Written by Customer Service on November 25, 2025. Posted in Public Companies.

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trialKisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early and metastatic breast cancer patientsBasel, November 25, 2025 – Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium® (SABCS). Featured among these latest advances in hematology and oncology are 11...

ABN AMRO to sell Alfam to Rabobank

Written by Customer Service on November 25, 2025. Posted in Mergers And Acquisitions.

ABN AMRO to sell Alfam to RabobankPersonal loans offered via a third-party arrangement 25 November 2025 Today, ABN AMRO announces that it has reached an agreement on the sale of its fully-owned subsidiary Alfam, ABN AMRO’s personal loan business, to Rabobank. ABN AMRO will continue to offer personal loans to its clients, now via a third-party arrangement with Rabobank. The personal loans market is highly competitive, making scale increasingly important. By joining forces with Rabobank, a well-regarded and reliable partner, clients will continue to receive high-quality service, building on the strong foundation that Alfam has established. The agreement also aligns with ABN AMRO’s strategic focus on simplifying the organisation to further improve operational performance. The transaction will lead to a positive impact on ABN AMRO’s...

Central Iron Ore Limited Results of the Shareholders Meeting

Written by Customer Service on November 25, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Central Iron Ore Limited (CIO – TSX.V) (“CIO” or “the Company”) is pleased to announce the results of its annual meeting of shareholders held on November 25, 2025. The shareholders approved, by a majority of votes, a resolution to elect the following directors: Richard Homsany, Anthony Howland-Rose, David Deitz and Paul Richardson. The shareholders, by a majority of votes, proceeded with the appointment of Moore Australia Audit (WA) as auditors of the Corporation and approved the continuation of the 10% rolling stock option plan. For more information, please contact: David Deitz, Director Tel.: +61 411 858 830 Warning The TSX Venture Exchange and its regulatory services provider (as is attributed to this term in the policies of the TSX Venture Exchange) assume...

MoneyHero Group partners with InsureMO to expand digital insurance access in the Philippines

Written by Customer Service on November 25, 2025. Posted in Public Companies.

MANILA, Philippines, Nov. 25, 2025 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced a strategic partnership with InsureMO, an insurance innovation infrastructure platform, to expand digital insurance product offerings in the Philippines through MoneyHero’s local brand, Moneymax. The Philippines has one of the lowest insurance penetration rates in Asia, at around 2% of GDP compared to the regional average of 4–5%, despite being one of the fastest-growing insurance markets. Motor insurance in particular is notably under-served: only about 1 in 3 vehicles on the road has comprehensive insurance coverage, with most drivers relying...

Nokia introduces MantaRay SON to NTT DOCOMO’s multi-vendor 5G network

Written by Customer Service on November 25, 2025. Posted in Public Companies.

Nokia introduces MantaRay SON to NTT DOCOMO’s multi-vendor 5G networkNokia and NTT DOCOMO partner to revolutionize 5G Operations in Japan with MantaRay SON Autonomous solution enhances 5G network efficiency, customer experience, and operational cost savings in Japan25th November 2025Espoo, Finland – Nokia today announced its collaboration with Japan’s NTT DOCOMO, INC. (“DOCOMO”) to deploy its autonomous MantaRay SON Self-Organizing Networks solution in DOCOMO’s multi-vendor LTE and 5G radio access network (RAN). This marks the first implementation in Japan of Nokia’s 5G base station combined with DOCOMO’s operation systems, enabling advanced automation and operational efficiency for 5G operations. The deployment is underway and is expected to improve operational efficiency and enhance the experience for DOCOMO’s customers. Nokia’s...

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Written by Customer Service on November 25, 2025. Posted in Public Companies.

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous injection) (code: JS001sc) or toripalimab injection (code: JS001) in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small-cell lung cancer (“NSQ-NSCLC”) (NCT06505837). Junshi Biosciences plans to submit a new drug application (“NDA”) to the regulatory authorities in the near future. According...

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Written by Customer Service on November 25, 2025. Posted in Public Companies.

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company’s novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), by the renowned scientific journal Signal Transduction and Targeted Therapy (Impact Factor: 52.7). The published results demonstrated promising efficacy and safety of olverembatinib in patients with succinate dehydrogenase...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals